Innovation, Ownership and Opportunity: Why Commercialization Begins During Clinical Research, Not After

Why Commercialization Readiness Should Come Before Spending Development Dollars

The greatest legal risks in commercialization often arise before anyone uses the word “commercialization.” Long before an innovation or research asset is licensed, transferred, deployed or otherwise commercialized, a startup is formed or an industry partner is identified, research organizations make decisions that affect ownership, control, regulatory strategy, payment pathways and future economic value. By the time proof of concept is achieved, many of those decisions are difficult, expensive or impossible to unwind. Organizations that delay commercialization planning frequently discover that important strategic options have already narrowed.

Commercialization considerations often arise before an innovation exists in a market-ready form. For purposes of this discussion, an “innovation” may include a new or improved method, process, technology, service, product, care model, software or data-enabled tool or other research-generated asset. Ownership rights, funding restrictions, data-use limitations, conflict-management obligations, pathways for reimbursement, payment or other compensation and regulatory requirements may attach or be affected during the research phase and shape future commercialization opportunities. Federal invention-management requirements applicable to federally funded research provide one example. The Bayh-Dole Act and its implementing regulations establish obligations relating to invention disclosure, title election and patent management during the research process rather than at the point of commercialization. See 35 U.S.C. § 200 (stating that a principal objective of the Bayh-Dole Act is to promote utilization of inventions arising from federally supported research and development); see also 37 C.F.R. § 401.14(c)(1)–(2) (requiring timely disclosure of subject inventions and election of title under standard funding agreement terms).

Many research institutions, academic medical centers and health systems continue to view commercialization as a downstream event that begins after proof of concept. Legally, however, commercialization often begins much earlier, when researchers and organizations first make decisions regarding the design, development, validation, implementation or delivery of an innovation, research subject informed consent, external or internal funding, conflicts management, regulatory strategy and asset stewardship.

When Does Commercialization Begin?

Commercialization begins when researchers and management start making decisions that influence the future development, ownership, control and commercialization of a research asset.

These decisions frequently occur at the earliest stages of a project and may include:

• Determining ownership of intellectual property and structuring limitations on subsequent use of pre-existing intellectual property;
• Identifying viable pathways for reimbursement, payment or other compensation for the anticipated innovation;
• Drafting informed consent documents and research protocols;
• Establishing rights in clinical data, biospecimens, methods, processes, care models, workflows, know-how, software, algorithms, digital tools, platforms, service offerings and other research outputs;
• Structuring sponsored research arrangements and vendor relationships;
• Selecting a regulatory pathway;
• Evaluating investigator relationships with industry;
• Determining whether an innovation will be developed, validated, implemented or scaled internally or in collaboration with a third party; and
• Determining whether the resulting innovation, research asset or underlying intellectual property will be licensed, sold, transferred, deployed or advanced through a startup company, strategic collaboration, service arrangement or other commercialization pathway.

Commercialization-related issues also arise during institutional review board (“IRB”) review, conflict-of-interest review and innovation-center governance processes. Decisions made at these stages may affect future rights in data and biospecimens, the ability to pursue commercial partnerships and the institution’s management of investigator and institutional conflicts. See 45 C.F.R. § 46.116(a) (establishing general requirements for legally effective informed consent); see also 45 C.F.R. § 46.111(a)(7) (requiring adequate protections for privacy and confidentiality); see also 21 C.F.R. §§ 50.20, 56.111(a) (establishing FDA informed-consent and IRB approval requirements).

Five Legal Questions To Ask Before Spending Development Dollars

1. Who Owns the Resulting Intellectual Property?

Ownership disputes remain among the most common barriers to successful commercialization.

Research collaborations often involve multiple intellectual property right holders, institutions, investigators, sponsors, contractors, consultants and industry participants. Before significant investment occurs, organizations should confirm ownership rights, scope of use restrictions, assignment obligations, inventor obligations, joint ownership implications and restrictions affecting background intellectual property.

For federally funded research, intellectual-property obligations arise early in the innovation lifecycle. Bayh-Dole implementing regulations require disclosure of subject inventions and election of title within prescribed timeframes. See 37 C.F.R. § 401.14(c)(1)–(2) (requiring disclosure of subject inventions and election of title by funding recipients).

2. Do Consent Documents and Research Governance Support Future Commercialization?

Many of today’s most valuable research assets consist of clinical datasets, biospecimen repositories, genomic information, methods, processes, care models, workflows, know-how, software, algorithms, digital tools, platforms, service offerings, registries and artificial-intelligence tools.

Organizations should evaluate whether informed consent documents, authorizations, protocol language, privacy disclosures and governance policies support anticipated future uses. Particular attention should be given to data sharing, future research uses, biospecimen restrictions, collaborator rights and commercialization-related limitations.

Consent and governance decisions made at the outset of a project often influence the future utility and value of research-generated assets. See 45 C.F.R. § 46.116(b)–(c) (required elements of informed consent, including disclosures necessary for informed decision-making).

3. Is the Funding Structure Consistent With Commercialization Objectives?

Funding arrangements frequently contain provisions that affect future commercialization flexibility. Examples include sponsor licensing rights, rights of first negotiation, exclusivity provisions, publication restrictions, milestone obligations and revenue-sharing requirements.

Similarly, available pathways for future reimbursement, payment or other commercialization-related compensation should be considered at the outset and revisited as the innovation evolves. Depending on the nature of the innovation, organizations should evaluate (1) applicable coverage, coding, payment, procurement, contracting, licensing, subscription, service fee, value-based payment and direct purchase pathways; (2) restrictions imposed by federal, state and commercial payors; and (3) potential customers both within and outside traditional payor programs.

Where research is supported by federal funding, the Bayh-Dole Act may create additional statutory obligations affecting future licensing and commercialization strategies. See 35 U.S.C. § 202(c)(4) (requiring inclusion of a nonexclusive, irrevocable, paid-up government license in subject inventions); see also 35 U.S.C. § 204 (imposing certain domestic manufacturing requirements applicable to exclusive licenses).

Organizations benefit from evaluating whether funding terms align with long-term commercialization objectives before substantial development resources are committed. Early-stage funding decisions can embed obligations such as government-use rights, diligence requirements, manufacturing or payor constraints that may later limit flexibility in licensing, partnering or exit transactions. Proactive diligence at the outset can help avoid costly restructuring or renegotiation downstream.

4. Are Conflicts of Interest and Conflicts of Commitment Being Managed Early?

Commercialization opportunities frequently arise from the work of investigators who serve in multiple roles, including researcher, inventor, consultant, founder, board member or owner.

Organizations should assess financial conflicts of interest, conflicts of commitment, disclosure obligations, research oversight requirements and conflict-management procedures.

For example, federal regulations governing Public Health Service-funded research require institutions to identify, review, manage and report certain financial conflicts of interest. See 42 C.F.R. § 50.605(a) (requiring institutional review and management of financial conflicts of interest related to federally funded research).

Early conflict review promotes transparency, protects research integrity and supports future commercialization activities.

5. Are Tax-Exempt and Charitable Asset Stewardship Considerations Applicable?

For tax-exempt health systems, academic medical centers and research institutions, commercialization planning should include an assessment of exempt-purpose requirements and stewardship responsibilities.

The Internal Revenue Service recognizes that tax-exempt organizations may engage in research, technology transfer and collaborations with for-profit entities when structured to further charitable purposes. Tax-exempt organizations must also avoid impermissible private benefit and private inurement, among other requirements. See, e.g., I.R.C. § 501(c)(3); Treas. Reg. § 1.501(c)(3)-1(c)(2) (prohibiting private inurement); Treas. Reg. § 1.501(c)(3)-1(d)(1)(ii) (requiring organizations to serve public rather than private interests); Rev. Rul. 98-15, 1998-1 C.B. 718 (analyzing exempt-organization participation in a joint venture with a for-profit entity); Rev. Rul. 2004-51, 2004-1 C.B. 974 (addressing exempt-organization participation in an ancillary joint venture).

Many commercialization opportunities are built upon assets developed using charitable resources, including clinical data, biospecimen repositories, research infrastructure, institutional reputation, investigator time and intellectual property. Commercialization planning should therefore include consideration of both transaction value and stewardship obligations associated with those assets.

Commercialization Readiness Assessment

A commercialization readiness assessment conducted before major development expenditures can help identify legal, regulatory and governance issues that may constrain future opportunities.

At a minimum, the assessment should evaluate:

• Intellectual-property ownership, use restrictions and protection strategy;
• Informed-consent and research-governance considerations;
• Data rights and asset inventory;
• Research agreements and funding restrictions;
• Regulatory pathway considerations;
• Conflict of interest and conflict of commitment management;
• Tax-exempt compliance and charitable asset stewardship; and
• Readiness for future licensing, reimbursement, payment, service delivery, deployment, financing, partnership, acquisition or other commercialization

Key Takeaways

• Commercialization rarely begins when a licensing agreement is signed or a startup company is formed. More often, it begins when a researcher and organization first make decisions regarding design, development, ownership, consent, governance, funding, conflicts management, regulatory strategy and control of research-generated assets.
• Early commercialization readiness assessments help institutions preserve strategic flexibility, protect valuable research assets, satisfy regulatory and tax-exemption requirements and support the translation of research into public benefit.

For guidance specific to innovation and commercialization endeavors, organizations evaluating research initiatives, development investments or commercialization opportunities are encouraged to contact:

• Rebecca Merrill at remerrill@hallrender.com or (984) 244-5383;
• Summer Martin at smartin@hallrender.com or (984) 244-5382;
• John Tyson at jtyson@hallrender.com or (317) 429-3664; or
• Your primary Hall Render contact.